SCHEMBL25819188

SCHEMBL25819188

Cc1ccc(-c2ccc(N3CCC4(CC3)OCCO4)c(F)c2)c(OCc2ccccc2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.39
GRM2 Q14416 1/20 0.38
ALDH1A1 P00352 9/20 0.38
KDM4E B2RXH2 5/20 0.38
HPGD P15428 5/20 0.38
L3MBTL1 Q9Y468 5/20 0.38
LMNA P02545 4/20 0.38
MAPK1 P28482 4/20 0.38
HCRTR1 O43613 3/20 0.38
MAPT P10636 3/20 0.38
GAA P10253 5/20 0.36
HSD17B10 Q99714 5/20 0.36
TDP1 Q9NUW8 4/20 0.36
POLB P06746 2/20 0.36
CASP1 P29466 2/20 0.36
CASP7 P55210 2/20 0.36
ATM Q13315 1/20 0.36
HRH4 Q9H3N8 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25822289 0.90 GRM5 (0.39) FFAR4GRM2ALDH1A1KDM4EHPGD
SCHEMBL30475477 0.90 GRM5 (0.39) FFAR4GRM2ALDH1A1KDM4EHPGD
SCHEMBL25935224 0.85 FFAR4 (0.44) FFAR4ALDH1A1HPGDLMNAMAPK1
SCHEMBL25819403 0.83 FFAR4 (0.42) FFAR4GRM2HRH4GRM5
SCHEMBL25935221 0.82 FFAR4 (0.41) FFAR4ALDH1A1HPGDL3MBTL1LMNA
SCHEMBL25935028 0.82 FFAR4 (0.49) FFAR4HRH4GRM5
SCHEMBL25819203 0.80 FFAR4 (0.61) FFAR4
SCHEMBL25935256 0.80 FFAR4 (0.50) FFAR4HRH4GRM5
SCHEMBL25819407 0.80 FFAR4 (0.42) FFAR4KDM4EGRM5
SCHEMBL31251917 0.80 GRM5 (0.38) GRM2ALDH1A1KDM4EHPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 FFAR4 4754/4885GRM2 2587/4885ALDH1A1 4008/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 FFAR4 4733/4885GRM2 1100/4885ALDH1A1 2752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.